A CD8 T-cell epitope variant enhances immune targeting to a recombinant picornavirus vaccine antigen

Viral Immunology

Volumn 27, Issue 7, 2014, Pages 361-366

  Bell, Michael P ^a   Renner, Danielle N ^b   Johnson, Aaron J ^a,b   Pavelko, Kevin D ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS RNA; VIRUS VACCINE; VIRUS VECTOR; ERBB2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA MODIFICATION; IMMUNE RESPONSE; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PICORNAVIRUS; PICORNAVIRUS INFECTION; RNA VIRUS; VIRUS GENOME; VIRUS MUTATION; VIRUS RECOMBINANT; ANIMAL; FEMALE; GENETIC ENGINEERING; GENETIC VARIABILITY; GENETICS; IMMUNOLOGY; METABOLISM; PICORNAVIRIDAE INFECTIONS; THEILOVIRUS;

ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; FEMALE; GENETIC ENGINEERING; GENETIC VARIATION; MICE; PICORNAVIRIDAE INFECTIONS; RECEPTOR, ERBB-2; THEILOVIRUS; VIRAL VACCINES;

EID: 84907022501     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0045     Document Type: Article

References (31)

1. Andreansky SS, Stambas J, Thomas PG, Xie W, Webby RJ, and Doherty PC. Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8 +-T-cell responses. J Virol 2005;79:4329-4339.
2. Bell MP, Renner DN, Johnson AK, and Pavelko KD. An elite controller of picornavirus infection targets an epitope that is resistant to immune escape. PLoS One 2014;9: e94332.
3. Borson ND, Paul C, Lin X, Nevala WK, Strausbauch MA, Rodriguez M, and Wettstein PJ. Brain-infiltrating cytolytic T lymphocytes specific for Theiler's virus recognize H2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue. J Virol 1997;71:5244-5250.
4. Burrows SR, Elkington RA, Miles JJ, et al. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype. J Immunol 2003;171:1407-1412.
5. del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, and Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995;154:685-693.
6. Denic A, Zoecklein L, Kerkvliet J, et al. Transgenic expression of viral capsid proteins predisposes to axonal injury in a murine model of multiple sclerosis. Brain Pathol 2011;21:501-515.
7. Dougan M, and Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
8. Falk K, Rotzschke O, Stevanovic S, Jung G, and Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351:290-296.
9. Farrington LA, Smith TA, Grey F, Hill AB, and Snyder CM. Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection. J Immunol 2013;190:3410-3416.
10. Fleischhauer K, Tanzarella S, Wallny HJ, Bordignon C, and Traversari C. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201 + cytotoxic T cell line. J Immunol 1996;157:787-797.
11. Johnson AJ, Njenga MK, Hansen MJ, et al. Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28. J Virol 1999;73: 3702-3708.
12. Kim TS, and Perlman S. Protection against CTL escape and clinical disease in a murine model of virus persistence. J Immunol 2003;171:2006-2013.
13. LaFrance-Corey RG, and Howe CL. Isolation of braininfiltrating leukocytes. J Vis Exp 2011 Jun 13;(52). doi: 10.3791/2747.
14. Li XF, Deng YQ, Yang HQ, et al. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 2013;87:13694-13705.
15. Lyman MA, Lee HG, Kang BS, Kang HK, and Kim BS. Capsid-specific cytotoxic T lymphocytes recognize three distinct H-2D(b)-restricted regions of the BeAn strain of Theiler's virus and exhibit different cytokine profiles. J Virol 2002;76:3125-3134.
16. Mason JN, Elbahesh H, and Russell CJ. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines. J Virol 2013;87:5959-5969.
17. McDole J, Suidan G, Boespflug E, et al. A translatable molecular approach to determining CD8 T-cell epitopes in TMEV infection. Hum Immunol 2008;69:805-810.
18. Mendez-Fernandez YV, Johnson AJ, Rodriguez M, and Pease LR. Clearance of Theiler's virus infection depends on the ability to generate a CD8 + T cell response against a single immunodominant viral peptide. Eur J Immunol 2003;33:2501-2510.
19. Moutaftsi M, Peters B, Pasquetto V, et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8 +)-cell responses to vaccinia virus. Nat Biotechnol 2006;24:817-819.
20. Nava-Parada P, Forni G, Knutson KL, Pease LR, and Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007;67:1326-1334.
21. Pavelko KD, Bell MP, Karyampudi L, et al. The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Mol Ther 2013;21:1087-1095.
22. Pavelko KD, Girtman MA, Mitsunaga Y, et al. Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy. PLoS One 2011;6:e20217.
23. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009;16:1709-1719.
24. Reddy PS, Burroughs KD, Hales LM, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007;99:1623-1633.
25. Sato S, Zhang L, Kim J, et al. A neutralization site of DA strain of Theiler's murine encephalomyelitis virus important for disease phenotype. Virology 1996;226:327-337.
26. Schirmbeck R, Reimann J, Kochanek S, and Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vectorencoded transgenic antigens. Mol Ther 1996;16:1609-1616.
27. Sette A, and Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 1999;50:201-212.
28. Smith CL, Dunbar PR, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005;113:259-266.
29. Smith CL, Mirza F, Pasquetto V, et al. Immunodominance of poxviral-specific CTL in a human trial of recombinantmodified vaccinia Ankara. J Immunol 2005;175:8431-8437.
30. Tatsis N, and Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004;10:616-629.
31. Webby RJ, Andreansky S, Stambas J, et al. Protection and compensation in the influenza virus-specific CD8 + T cell response. Proc Natl Acad Sci USA 2003;100:7235-7240.